Joshua Linscott, MD, PhD
Joshua Linscott, MD, PhD
Specialty: Urology
Program: Genitourinary Oncology
Language(s): English
-
Overview
Cancer Focus:
Bladder Cancer, Kidney (Renal Cell) Cancer, Prostate CancerDr. Linscott received his PhD in Pharmacology from Weill Cornell Medical College, New York City. He received his MD degree at Tufts University School of Medicine, Boston, Massachusetts. Dr. Linscott completed a Urology Residency at Maine Medical Center, Portland, followed by Urologic Oncology fellowship at Moffitt Cancer Center, Tampa.
Dr. Linscott specializes in the treatment of patients with early and locally advanced bladder cancer, kidney cancer, and prostate cancer. He is a translational researcher focused on urothelial carcinoma, with a particular interest in the discovery and development of urinary cell-free DNA biomarkers. Dr. Linscott’s research goals include defining patterns of urinary cell-free DNA methylation as predictors of treatment response and disease progression, as well as studying the tumor immune microenvironment in BCG-treated patients using spatial transcriptomics.
-
Publications
- Zhao D, Khatri VM, Nakashima JY, Chadha J, Chatwal M, Zhang J, Ionescu F, Linscott JA, Li R, Poch M, Sexton W, Yu A, Spiess PE, Zemp L, Gilbert SM, Manley B, Yin V, Jain R, Torres-Roca J, Johnstone P, Yamoah K, Grass GD. Early Detection of Metastatic Progression by Circulating Tumor DNA in Patients Undergoing Bladder-Preserving Trimodality Therapy. J Urol. 2026 Mar.215(3):305-315. Pubmedid: 41231842.
- Chatzkel J, Linscott J, Daniel Grass G, Li R. Urothelial Cancer: Leveraging Circulating Tumor DNA To Avoid Unnecessary Bladder-directed and Systemic Therapies. Eur Urol Focus. 2026 Jan.12(1):38-40. Pubmedid: 40716995.
- Guske C, Immen N, Conant D, Laborde J, Linscott J, Hayes M, Jazayeri SB, Fazili A, Siegel E, Dessureault S, Sanchez J, Stefanou A, Manley B, Felder S. Short- and Intermediate-Term Morbidity Following Total Pelvic Exenteration in Colorectal Cancer. Cancer Control. 2025 Jan.32. Pubmedid: 39848249. Pmcid: PMC11758541.
- Li R, Linscott J, Catto JWF, Daneshmand S, Faltas BM, Kamat AM, Meeks JJ, Necchi A, Pradere B, Ross JS, van der Heijden MS, van Rhijn BWG, Loriot Y. FGFR Inhibition in Urothelial Carcinoma. Eur Urol. 2025 Feb.87(2):110-122. Pubmedid: 39353825.
- Jazayeri SB, DiNatale RG, Guske C, Harrs C, Linscott J, Xu H, Davaro F, Wen L, Spiess PE, Sexton WJ, Gilbert SM, Zemp L, Poch MA, Li R. Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer: Survival Benchmarks, Bladder-sparing Strategies, and Implications for Trial Design. Eur Urol Focus. 2025 Dec. Pubmedid: 41421932.
- Guske C, Jazayeri SB, Harrs C, Rao N, Davaro F, Xu H, Zemp L, Yu A, Gilbert SM, Poch M, Spiess PE, Sexton W, Linscott J, Li R. Assessing the Impact of Treatment Timing Protocols in Clinical Trials for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. 2025 Aug.8(4):888-892. Pubmedid: 40670271.
- Linscott J, Li R. Letter: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 Oct.212(4):624-625. Pubmedid: 38912644.
- Linscott JA, Miyagi H, Murthy PB, Yao S, Grass GD, Vosoughi A, Xu H, Wang X, Yu X, Yu A, Zemp L, Gilbert SM, Poch MA, Sexton WJ, Spiess PE, Li R. From Detection to Cure - Emerging Roles for Urinary Tumor DNA (utDNA) in Bladder Cancer. Curr Oncol Rep. 2024 Aug.26(8):945-958. Pubmedid: 38837106.
- Linscott JA, Meeks JJ, Dyrskjøt L, Li R. The Elusive Horizon: Biomarkers in Urothelial Carcinoma. Eur Urol. 2024 Apr.85(4):317-319. Pubmedid: 38278663.
- Linscott JA, Sexton WJ. Editorial Comment. J Urol. 2024 Apr.211(4):573-574. Pubmedid: 38241201.
-
Grants
- Title: Utilizing Cell Free DNA to Detect Minimal Residual Disease and Monitor Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer
Award Number:
Sponsor: American Urological Association (AUA)
Linscott, J. (PD/PI)
- Title: Utilizing Cell Free DNA to Detect Minimal Residual Disease and Monitor Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer
-
Patient Comments
0 patients rated this provider
The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Learn more about our patient satisfaction surveyComments
Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.
Learn more about our patient comments
We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:
Learn more about our patient satisfaction survey, ratings and comments